Intellectual Product – Page 18

Vertex’s CASGEVY Marks Historic Milestone with First Commercial Patient Infusions, Paving the Way for 2025 Launches

6 months ago talkbio0Tagged Anemia, Sickle Cell, Approved, Casgevy, commercial, CRISPR/Cas9, gene therapy, Infusion procedures, launches, United States Food and Drug Administration

CASGEVY, Vertex Pharmaceuticals, gene therapy, sickle cell disease, beta thalassemia, CRISPR/Cas9, FDA approval, commercial patient infusions, 2025 launches.

Historic Settlement: Lacks Family Reaches Agreement with Thermo Fisher Scientific Over Unjust Enrichment from HeLa Cells

6 months ago talkbio0Tagged Biotechnology, Consent, HeLa Cells, Henrietta Lacks, racial injustice, Science, settlement, Thermo Fisher

Henrietta Lacks, HeLa cells, Thermo Fisher Scientific, unjust enrichment, racial injustice, medical ethics, consent, biotechnology, settlement.

FDA Advisory Committee Rejects Lexicon’s Zynquista for Type 1 Diabetes and Chronic Kidney Disease

6 months ago talkbio0Tagged Advisory Committees, Chronic Kidney Diseases, Drug Approval, lexicon, United States Food and Drug Administration, Zynquista

FDA, Lexicon Pharmaceuticals, Zynquista, sotagliflozin, type 1 diabetes, chronic kidney disease, FDA advisory committee, drug approval

Roche Advances Alzheimer’s Disease Diagnosis with Breakthrough Blood Test

6 months ago talkbio0Tagged Alzheimer 's disease, Amyloid, Diagnosis, Eli, Eli Lilly, Identifier, Medical Devices, Pathology, Roche, Roche (company), United States Food and Drug Administration

Alzheimer’s disease, blood test, Roche, Eli Lilly, FDA breakthrough device designation, pTau217, amyloid pathology, early diagnosis.

Biogen Raises Profit Guidance Amid Leqembi Growth and MS Sales Decline

6 months ago talkbio0Tagged Biogen, Drug Industry, earnings, Leqembi, Multiple Sclerosis, profit, Report (document)

Biogen, profit guidance, Leqembi, multiple sclerosis, earnings report, pharmaceutical industry

FDA Advisory Committee Votes Against Zynquista for Type 1 Diabetes and Chronic Kidney Disease, Despite Support for Subgroup Benefits

6 months ago talkbio0Tagged (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol, Advisory Committees, Chronic Kidney Diseases, Diabetes Mellitus, Insulin-Dependent, Glycemic Control, Inhibitor, lexicon, SGLT1/SGLT2, United States Food and Drug Administration, Zynquista

FDA Advisory Committee, Zynquista (sotagliflozin), Type 1 Diabetes (T1D), Chronic Kidney Disease (CKD), Glycemic Control, SGLT1/SGLT2 Inhibitor, Lexicon Pharmaceuticals